December 5-6th, 2017

San Diego, CA

Speakers from 2016

Expand/Collapse

Nigel Pheasey
Senior Scientist
Amgen

Day One

Wednesday December 7th, 2016

10.10 | PANEL: Then and Now: T Vec the Journey to Market

Faris Farassati
Cancer Scientist
Kansas City Veteran Affairs Medical Center

Day One

Wednesday December 7th, 2016

09.40 | Cancer Stem Cells as Targets for Oncolytic Viruses

Charles Morris
Chief Development Officer
PsiOxus Therapeutics

Day One

Wednesday December 7th, 2016

16.10 | Panel Session: The Future of Combination Strategies

Day Two

Thursday December 8th, 2016

11.10 | Tumor-Specific Immuno-Gene Therapy: Using Enadenotucirev as an Oncolytic Vector System to Deliver Multiple Immune-Modulatory Genes to Cancer Cells

Joshua Schimmer
Managing Director, Biotechnology Research Analyst
Piper Jaffray & Co

Day Two

Thursday December 8th, 2016

15.40 | Panel Session: Funding and Investment to Further the Development of Oncolytic Virotherapies

Matt Mulvey
CEO
Benevir Biopharm

Day Two

Thursday December 8th, 2016

15.40 | Panel Session: Funding and Investment to Further the Development of Oncolytic Virotherapies

09.10 | Oncolytic Viruses and Immunity: Friends? Enemies? Frenemies?

Antonio Chiocca
Professor & Chairman, Department of Neurosurgery
Brigham & Women’s Hospital/ Harvard Medical School

Day One

Wednesday December 7th, 2016

17.00 | Chairman’s Closing Remarks

10.10 | PANEL: Then and Now: T Vec the Journey to Market

09.00 | Chairman’s Opening Remarks

Day Two

Thursday December 8th, 2016

16.40 | Chairman’s Closing Remarks: The Future of Onoclytic Virotherapies

10.10 | Improving Oncolysis and Therapy with Pharmacologic Modulation

09.00 | Chairman’s Opening Remarks

Timothy Coté
Principle & CEO
Coté Orphan Formerly from the FDA

Day Two

Thursday December 8th, 2016

16.10 | Getting Orphan Designation to Make Viral Oncology Products More Valuable

Antonio Marchini
Principal Investigator
German Cancer Research Center (DKFZ)

Day One

Wednesday December 7th, 2016

16.10 | Panel Session: The Future of Combination Strategies

Frank Tufaro
CEO
DNAtrix

Day Two

Thursday December 8th, 2016

14.40 | Panel Session: Considerations for Creating the Next Generation of Commerically Viable Oncolytic Virotherapies

14.10 | Outsourcing and Partnering for Commercial Grade Manufacturing

Osvaldo Podhajcer
Chief, Laboratory of Molecular & Cellular Therapy
Instituto Leloir

Day One

Wednesday December 7th, 2016

11.40 | Novel Stroma-Targeted and Microenvironment-Inducible Oncolytic Adenoviruses (OAVs)

Angelica Loskog
CEO
Lokon Pharma

Day Two

Thursday December 8th, 2016

15.40 | Panel Session: Funding and Investment to Further the Development of Oncolytic Virotherapies

11.40 | Activating the CD40 Pathway by CD40L-Armed Virus Therapeutics to Initiate Robust Cancer Immunity

Samuel Rabkin
Professor of Neurosurgery
Massachusetts General Hospital

Day Two

Thursday December 8th, 2016

09.40 | Combinatorial Strategies with Oncolytic Herpes Simplex Virus: Killing for Success

Gautam Sanyal
Fellow, R&D
MedImmune

Day Two

Thursday December 8th, 2016

13.40 | Analytics Guided Development of Recombinant Newcastle Disease Virus for Oncolytic Therapy

Hideki Kasuya
Chairman, Associate Professor
Nagoya University

Day One

Wednesday December 7th, 2016

15.10 | Effectiveness Comparison of Different Routes of Administration of Oncolytic Virus in Abdominal Tumors

Brad Thompson
CEO
Oncolytics Biotech

Day One

Wednesday December 7th, 2016

14.10 | Immune and Genetic Markers in Randomized Clinical Studies using REOLYSIN®

Howard Kaufman
Associate Director Clinical Science
Rutgers Cancer Institute of New Jersey

Day One

Wednesday December 7th, 2016

10.10 | PANEL: Then and Now: T Vec the Journey to Market

Monika Lusky
Director & Senior Project Leader
Transgene

Day One

Wednesday December 7th, 2016

14.40 | Poxvirus Based Oncolytic Immunotherapy: Preclinical and Clinical Development

Daniel Katzman
CEO
Unleash Immune Oncolytics

Day Two

Thursday December 8th, 2016

14.40 | Panel Session: Considerations for Creating the Next Generation of Commerically Viable Oncolytic Virotherapies

Marc Froeschke
Head of Process Development
ViraTherapeutics

Joe Connor
CEO
Virttu Biologics

Day One

Wednesday December 7th, 2016

12.10 | Immune Cell Recruitment and Anti-Tumor IgG Responses Following Intrapleural Administration of the Oncolytic HSV Seprehvir in Patients with Malignant Pleural Mesothelioma

David Curiel
Director, Biologic Therapeutic Center
Washington University School of Medicine

Day Two

Thursday December 8th, 2016

12.10 | Biologically Targeted Virotherapy for Metastatic Cancer

Stephen Thorne
CSO
Western Oncolytics

Day One

Wednesday December 7th, 2016

16.10 | Panel Session: The Future of Combination Strategies

09.10 | Oncolytic Viral Interaction with the Host Immune Response

Timothy Cripe
Chief Division of Hematology, Oncology & Bone Marrow Transplantation
Nationwide Children’s Hospital

Day One

Wednesday December 7th, 2016

12.40 | Preclinical and Preliminary Phase I Clinical Safety and Efficacy Studies of Intravenously Administered Seprehvir, an Oncolytic Herpes Viroimmunotherapeutic